Primary |
Breast Cancer |
43.1% |
Hodgkin's Disease |
10.6% |
Non-hodgkin's Lymphoma |
10.4% |
Multiple Myeloma |
4.8% |
Lymphoma |
4.4% |
Burkitt's Lymphoma |
3.9% |
Adult T-cell Lymphoma/leukaemia |
2.8% |
Diffuse Large B-cell Lymphoma |
2.8% |
Precursor T-lymphoblastic Lymphoma/leukaemia |
2.5% |
Acute Lymphocytic Leukaemia |
2.2% |
Primary Effusion Lymphoma |
2.1% |
Prostate Cancer |
1.7% |
Chronic Myeloid Leukaemia |
1.5% |
Leukaemia Plasmacytic |
1.2% |
Bone Sarcoma |
1.1% |
Endometrial Cancer |
1.1% |
Ill-defined Disorder |
1.1% |
Hodgkin's Disease Stage Iv |
1.0% |
Neuroblastoma |
1.0% |
Breast Cancer Metastatic |
0.8% |
|
Febrile Neutropenia |
12.5% |
Vomiting |
8.3% |
Sepsis |
7.6% |
Pneumonia |
6.9% |
Neutropenia |
5.6% |
Nausea |
4.9% |
Pulmonary Toxicity |
4.9% |
Pyrexia |
4.9% |
Cardiac Failure Congestive |
4.2% |
Cardiomyopathy |
4.2% |
Cellulitis |
4.2% |
Osteonecrosis |
4.2% |
Renal Failure Acute |
4.2% |
Thrombocytopenia |
4.2% |
White Blood Cell Count Decreased |
4.2% |
Pancytopenia |
3.5% |
Pneumonitis |
3.5% |
Cardiac Failure |
2.8% |
Colitis |
2.8% |
Death |
2.8% |
|
Secondary |
Multiple Myeloma |
21.9% |
Breast Cancer |
16.6% |
Hodgkin's Disease |
14.7% |
Non-hodgkin's Lymphoma |
7.0% |
Drug Use For Unknown Indication |
6.9% |
Acute Lymphocytic Leukaemia |
4.3% |
Diffuse Large B-cell Lymphoma |
4.2% |
Lymphoma |
3.0% |
B-cell Lymphoma |
2.9% |
Product Used For Unknown Indication |
2.6% |
Chemotherapy |
2.5% |
Prophylaxis |
2.3% |
Burkitt's Lymphoma |
1.8% |
Mantle Cell Lymphoma |
1.7% |
Breast Cancer Metastatic |
1.5% |
Bone Sarcoma |
1.4% |
Adult T-cell Lymphoma/leukaemia |
1.3% |
Chronic Lymphocytic Leukaemia |
1.1% |
Hypertension |
1.1% |
Pain |
1.1% |
|
Febrile Neutropenia |
10.2% |
Pyrexia |
8.8% |
Vomiting |
8.8% |
Sepsis |
7.5% |
Thrombocytopenia |
7.1% |
Myocarditis |
5.2% |
Pneumonia |
5.2% |
Acute Myeloid Leukaemia |
4.8% |
White Blood Cell Count Decreased |
4.6% |
Death |
4.4% |
Neutropenia |
4.0% |
Hypothyroidism |
3.8% |
Maternal Exposure During Pregnancy |
3.5% |
Stomatitis |
3.5% |
Treatment Related Secondary Malignancy |
3.5% |
Pancytopenia |
3.3% |
Hepatitis B |
3.1% |
Myelodysplastic Syndrome |
2.9% |
Osteonecrosis |
2.9% |
Pneumonitis |
2.9% |
|
Concomitant |
Breast Cancer |
18.5% |
Multiple Myeloma |
16.5% |
Chemotherapy |
9.6% |
Breast Cancer Metastatic |
6.8% |
Metastases To Bone |
6.7% |
Pain |
5.1% |
Prophylaxis |
5.0% |
Drug Use For Unknown Indication |
3.4% |
Non-hodgkin's Lymphoma |
3.2% |
Product Used For Unknown Indication |
3.1% |
B-cell Lymphoma |
3.1% |
Hypertension |
2.8% |
Hodgkin's Disease |
2.7% |
Depression |
2.3% |
Diffuse Large B-cell Lymphoma |
2.2% |
Nuclear Magnetic Resonance Imaging |
2.1% |
Neoplasm Malignant |
2.0% |
Lymphoma |
1.8% |
Eczema |
1.5% |
Acute Lymphocytic Leukaemia |
1.4% |
|
Weight Decreased |
12.8% |
Vomiting |
9.3% |
Tooth Extraction |
7.9% |
Weight Increased |
6.5% |
Febrile Neutropenia |
6.3% |
White Blood Cell Count Increased |
5.6% |
White Blood Cell Count Decreased |
4.6% |
Wound Drainage |
4.6% |
Pyrexia |
4.4% |
Thrombocytopenia |
4.0% |
Wheelchair User |
3.9% |
Wound Dehiscence |
3.9% |
Dyspnoea |
3.7% |
Wound Treatment |
3.7% |
Neutropenia |
3.5% |
Wheezing |
3.5% |
Wound Secretion |
3.3% |
Wound Debridement |
3.0% |
Palmar-plantar Erythrodysaesthesia Syndrome |
2.8% |
X-ray Abnormal |
2.8% |
|
Interacting |
Hodgkin's Disease |
40.0% |
Prophylaxis Of Nausea And Vomiting |
20.0% |
Anxiety |
10.0% |
Breast Cancer |
10.0% |
Bronchopulmonary Aspergillosis |
10.0% |
Supraventricular Tachycardia |
10.0% |
|
Drug Interaction |
25.0% |
Infusion Site Phlebitis |
25.0% |
Middle Insomnia |
25.0% |
Palpitations |
25.0% |
|